Parameters associated with a longer time to progression and a longer survival in the 124 patients with non-MALT MZL
| . | Time to Progression . | Survival . |
|---|---|---|
| Age (y) (<60 vs ≥60) | NS | NS |
| Performance status (0-1 vs ≥2) | NS | NS |
| Peripheral lymph nodes (yes/no) | P = .001 | NS |
| Abdominal or thoracic lymph nodes (yes/no) | NS | NS |
| Spleen involvement (yes/no) | P = .05 | NS |
| Stage (I-II vs III-IV) | NS | NS |
| Number of extranodal sites (0-1 vs ≥2) | NS | NS |
| Bulky tumor (yes/no) | NS | NS |
| β2-microglobulin level (<3 vs ≥3 mg/L) | NS | NS |
| LDH level (normal/abnormal) | NS | NS |
| Hemoglobin level (<12 vs ≥12 g/dL) | NS | NS |
| Blood involvement (yes/no) | P < .05 | NS |
| International Prognostic Index (0-1 vs 2 vs 3 vs 4-5) | NS | NS |
| . | Time to Progression . | Survival . |
|---|---|---|
| Age (y) (<60 vs ≥60) | NS | NS |
| Performance status (0-1 vs ≥2) | NS | NS |
| Peripheral lymph nodes (yes/no) | P = .001 | NS |
| Abdominal or thoracic lymph nodes (yes/no) | NS | NS |
| Spleen involvement (yes/no) | P = .05 | NS |
| Stage (I-II vs III-IV) | NS | NS |
| Number of extranodal sites (0-1 vs ≥2) | NS | NS |
| Bulky tumor (yes/no) | NS | NS |
| β2-microglobulin level (<3 vs ≥3 mg/L) | NS | NS |
| LDH level (normal/abnormal) | NS | NS |
| Hemoglobin level (<12 vs ≥12 g/dL) | NS | NS |
| Blood involvement (yes/no) | P < .05 | NS |
| International Prognostic Index (0-1 vs 2 vs 3 vs 4-5) | NS | NS |
LDH = lactic dehydrogenase; MALT = mucosa-associated lymphoid tissue; MZL = marginal zone B-cell lymphoma; NS = not significant.